Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Risk-free polio vaccine: Recombinant expression systems for production of stabilised virus-like particles

Sherry L. et al, (2024)

Publisher Correction: A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation.

Bahar MW. et al, (2022), Commun Biol, 5

Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris.

Sherry L. et al, (2022), Viruses, 14

Production and characterisation of stabilised PV-3 virus-like particles using Pichia pastoris

Sherry L. et al, (2022)

A conserved glutathione binding site in poliovirus is a target for antivirals and vaccine stabilisation

Bahar MW. et al, (2022)

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai W. et al, (2022), Cell, 185, 467 - 484.e15

Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines.

Bahar MW. et al, (2021), NPJ vaccines, 6

Plant-made polio type 3 stabilized VLPs—a candidate synthetic polio vaccine

Marsian J. et al, (2017), Nature Communications, 8

Structure of a VP1-VP3 Complex Suggests How Birnaviruses Package the VP1 Polymerase

Bahar MW. et al, (2013), Journal of Virology, 87, 3229 - 3236

Inhibition of Apoptosis and NF-κB Activation by Vaccinia Protein N1 Occur via Distinct Binding Surfaces and Make Different Contributions to Virulence

Maluquer de Motes C. et al, (2011), PLoS Pathogens, 7, e1002430 - e1002430

CS18-3. Modulation of apoptosis and pro-inflammatory signalling by vaccinia virus protein N1

de Motes M. et al, (2011), Cytokine, 56, 109 - 109

How vaccinia virus has evolved to subvert the host immune response

Bahar MW. et al, (2011), Journal of Structural Biology, 175, 127 - 134

Insights into the Evolution of a Complex Virus from the Crystal Structure of Vaccinia Virus D13

Bahar MW. et al, (2011), Structure, 19, 1011 - 1020

The N-Terminus of the RNA Polymerase from Infectious Pancreatic Necrosis Virus Is the Determinant of Genome Attachment

Graham SC. et al, (2011), PLoS Pathogens, 7, e1002085 - e1002085

Mapping the IκB Kinase β (IKKβ)-binding Interface of the B14 Protein, a Vaccinia Virus Inhibitor of IKKβ-mediated Activation of Nuclear Factor κB

Benfield CTO. et al, (2011), Journal of Biological Chemistry, 286, 20727 - 20735

Vaccinia Virus Proteins A52 and B14 Share a Bcl-2–Like Fold but Have Evolved to Inhibit NF-κB rather than Apoptosis

Graham SC. et al, (2008), PLoS Pathogens, 4, e1000128 - e1000128

Structure and Function of A41, a Vaccinia Virus Chemokine Binding Protein

Bahar MW. et al, (2008), PLoS Pathogens, 4, e5 - e5

Structure of CrmE, a Virus-encoded Tumour Necrosis Factor Receptor

Graham SC. et al, (2007), Journal of Molecular Biology, 372, 660 - 671

Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein

Cooray S. et al, (2007), Journal of General Virology, 88, 1656 - 1666

Load More

Include forthcoming?